Quantitative evaluation of a monoclonal antibody and its fragment as potential markers for pancreatic beta cell mass

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 7, 2005, Pages 381-387

  Hampe, C S ^a   Wallen, A R ^a   Schlosser, M ^b   Ziegler, M ^c   Sweet, Ian R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c Institut fur Diabetes 'Gerhardt Katsch'   (Germany)

Author keywords

Beta cell mass; Fab; Monoclonal antibodies; PET

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY K14D10; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ARTICLE; BINDING KINETICS; CELL SPECIFICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; INSULINOMA; NUCLEOTIDE SEQUENCE; PANCREAS ISLET BETA CELL; PLASMA CLEARANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BASE SEQUENCE; BINDING SITES, ANTIBODY; DIABETES MELLITUS, TYPE 1; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; IODINE RADIOISOTOPES; ISLETS OF LANGERHANS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RATS; RATS, INBRED F344; TISSUE DISTRIBUTION;

EID: 23044438069     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865716     Document Type: Article

References (30)

1. Adams GP, Schier R. Generating improved single-chain Fv molecules for tumor targeting. J Immunol Methods 1999; 231: 249-260
2. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 1992; 130: 167-178
3. Bazin-Redureau MI, Renard CB, Scherrmann JM. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 1997; 49: 277-281
4. Boyle CC, Paine AJ, Mather SJ. The mechanism of hepatic uptake of a radiolabelled monoclonal antibody. Int J Cancer 1992; 50: 912-917
5. Brinkmann U, Webber K, Di Carlo A, Beers R, Chowdhury P, Chang K, Chaudhary V, Gallo M, Pastan I. Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. Int J Cancer 1997; 71: 638-644
6. Buschard K, Brogren CH, Ropke C, Rygaard J. Antigen expression of the pancreatic beta-cells is dependent on their functional state, as shown by a specific, BB rat monoclonal autoantibody IC2. Apmis 1988; 96: 342-346
7. Camera L, Kinuya S, Garmestani K, Pai LH, Brechbiel MW, Gansow OA, Paik CH, Pastan I, Carrasquillo JA. Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts. Nucl Med Biol 1993; 20: 955-962
8. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, Wong WL, Rowland AM, Kotts CE, Carver ME et al. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology (NY) 1992; 10: 163-167
9. Casey JL, Napier MP, King DJ, Pedley RB, Chaplin LC, Weir N, Skelton L, Green AJ, Hope-Stone LD, Yarranton GT, Begent RH. Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study. Br J Cancer 2002; 86: 1401-1410
10. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE, Schlom J. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990; 82: 1191-1197
11. Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK. Pharmacokinetics and biodistribution of genetically-engineered antibodies. QJ Nucl Med 1998; 42: 225-241
12. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res 1986; 46: 3969-3978
13. DeNardo SJ, Peng JS, DeNardo GL, Mills SL, Epstein AL. Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Int J Rad Appl Instrum B 1986; 13: 303-310
14. Garnuszek P, Licinska I, Fiedor P, Mazurek AP. The synthesis, radioiodination and preliminary biological study of the new carboxylic derivatives of dithizone. Appl Radiat Isot 1998; 49: 1563-1571
15. Hampe CS, Lundgren P, Daniels TL, Hammerle LP, Marcovina SM, Lernmark A. A novel monoclonal antibody specific for the N-terminal end of GAD65. J Neuroimmunol 2001; 113: 63-71
16. Izard ME, Boniface GR, Hardiman KL, Brechbiel MW, Gansow OA, Walkers KZ. An improved method for labeling monoclonal antibodies with samarium-153: use of the bifunctional chelate 2-(p-isothiocyanatobenzyl)-6- methyldiethylenetriaminepentaacetic acid. Bioconjug Chem 1992; 3: 346-350
17. Kabat EA, Wu TT, Perry HM, Gottesman K, Foeller C. Sequences of Proteins of Immunological Interest. Washington, DC: Services US DoHaH, 1991
18. Konidaris C, Simonson W, Michelsen B, Papadopoulos GK. Specific monoclonal antibodies against the surface of rat islet beta cells. Cell Biol Int 2002; 26: 817-828
19. Logsdon CD, Moessner J, Williams JA, Goldfine ID. Glucocorticoids increase amylase mRNA levels, secretory organelles, and secretion in pancreatic acinar AR42J cells. J Cell Biol 1985; 100: 1200-1208
20. Malaisse WJ. On the track to the beta-cell. Diabetologia 2001; 44: 393-406
21. Milenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF, Whitlow M, Snoy P, Schlom J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991; 51: 6363-6371
22. Moore A, Bonner-Weir S, Weissleder R. Noninvasive in vivo measurement of beta-cell mass in mouse model of diabetes. Diabetes 2001; 50: 2231-2236
23. Mossner J, Logsdon CD, Williams JA, Goldfine ID. Insulin, via its own receptor, regulates growth and amylase synthesis in pancreatic acinar AR42J cells. Diabetes 1985; 34: 891-897
24. Neidhardt FC, Bloch PL, Smith DF. Culture medium for enterobacteria. J Bacteriol 1974; 119: 736-747
25. Padoa CJ, Banga JP, Madec AM, Ziegler M, Schlosser M, Ortqvist E, Kockum I, Palmer J, Rolandsson O, Binder KA, Foote J, Luo D, Hampe CS. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GA-D65Abs. Diabetes 2003; 52: 2689-2695
26. Sweet IR, Cook DL, Lernmark A, Greenbaum CJ, Krohn KA. Non-invasive imaging of beta cell mass: a quantitative analysis. Diabetes Technol Ther 2004b; 6: 652-659
27. Sweet IR, Cook DL, Lernmark A, Greenbaum CJ, Wallen AR, Marcum ES, Stekhova SA, Krohn KA. Systematic screening of potential beta-cell imaging agents. Biochem Biophys Res Commun 2004a; 314: 976-983
28. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999; 59: 347-352
29. Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 1993; 53: 3776-3783
30. Ziegler B, Lucke S, Kohler E, Hehmke B, Schlosser M, Witt S, Besch W, Ziegler M. Monoclonal antibody-mediated cytotoxicity against rat beta cells detected in vitro does not cause beta-cell destruction in vivo. Diabetologia 1992; 35: 608-613